Florian Klein

Summary

Affiliation: The Rockefeller University
Country: USA

Publications

  1. pmc Antibodies in HIV-1 vaccine development and therapy
    Florian Klein
    Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
    Science 341:1199-204. 2013
  2. pmc Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses
    Hugo Mouquet
    Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, United States of America
    PLoS ONE 6:e24078. 2011
  3. pmc HIV therapy by a combination of broadly neutralizing antibodies in humanized mice
    Florian Klein
    Laboratory of Molecular Immunology, The Rockefeller University, New York, New York 10065, USA
    Nature 492:118-22. 2012
  4. pmc Isolation of HIV-1-reactive antibodies using cell surface-expressed gp160Δc(BaL.)
    Christian Gaebler
    Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA Faculty of Medicine Carl Gustav Carus, Technische Universitat Dresden, D 01307 Dresden, Germany
    J Immunol Methods 397:47-54. 2013
  5. pmc Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding
    Johannes F Scheid
    Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
    Science 333:1633-7. 2011
  6. pmc Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization
    Florian Klein
    Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
    Cell 153:126-38. 2013
  7. pmc Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein
    Florian Klein
    Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
    J Exp Med 209:1469-79. 2012
  8. pmc HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice
    Joshua A Horwitz
    Laboratory of Molecular Immunology, Laboratory of Virology and Infectious Diseases, and Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065
    Proc Natl Acad Sci U S A 110:16538-43. 2013
  9. pmc A mouse model for HIV-1 entry
    John Pietzsch
    Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 109:15859-64. 2012
  10. pmc Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness
    John Pietzsch
    Laboratory of Molecular Immunology and Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, USA
    J Exp Med 207:1995-2002. 2010

Collaborators

Detail Information

Publications10

  1. pmc Antibodies in HIV-1 vaccine development and therapy
    Florian Klein
    Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
    Science 341:1199-204. 2013
    ..Moreover, the success of passive immunotherapy in small-animal models suggests that bNAbs may become a valuable addition to the armamentarium of drugs that work against HIV-1. ..
  2. pmc Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses
    Hugo Mouquet
    Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, United States of America
    PLoS ONE 6:e24078. 2011
    ....
  3. pmc HIV therapy by a combination of broadly neutralizing antibodies in humanized mice
    Florian Klein
    Laboratory of Molecular Immunology, The Rockefeller University, New York, New York 10065, USA
    Nature 492:118-22. 2012
    ..Thus, combinations of potent monoclonal antibodies can effectively control HIV-1 replication in humanized mice, and should be re-examined as a therapeutic modality in HIV-1-infected individuals...
  4. pmc Isolation of HIV-1-reactive antibodies using cell surface-expressed gp160Δc(BaL.)
    Christian Gaebler
    Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA Faculty of Medicine Carl Gustav Carus, Technische Universitat Dresden, D 01307 Dresden, Germany
    J Immunol Methods 397:47-54. 2013
    ..While this method is far less efficient than sorting with soluble envelope proteins, it isolated broadly neutralizing anti-HIV-1 antibodies that bind cell surface-expressed gp160Δc(BaL) but not soluble envelope proteins. ..
  5. pmc Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding
    Johannes F Scheid
    Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
    Science 333:1633-7. 2011
    ..Comparison of the crystal structure of one of the antibodies to the broadly neutralizing antibody VRC01 revealed conservation of the contacts to the HIV spike...
  6. pmc Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization
    Florian Klein
    Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
    Cell 153:126-38. 2013
    ..Thus, in bNAbs, FWRs play an essential role beyond scaffolding the CDR loops and their unusual contribution to potency and breadth should be considered in HIV-1 vaccine design...
  7. pmc Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein
    Florian Klein
    Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
    J Exp Med 209:1469-79. 2012
    ..Therefore, vaccines aimed at eliciting anti-HIV-1 serologic breadth and potency should not be limited to single epitopes...
  8. pmc HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice
    Joshua A Horwitz
    Laboratory of Molecular Immunology, Laboratory of Virology and Infectious Diseases, and Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065
    Proc Natl Acad Sci U S A 110:16538-43. 2013
    ..We conclude that immunotherapy reduces plasma viral load and cell-associated HIV-1 DNA and that decreasing the initial viral load enables single bNAbs to control viremia in hu-mice. ..
  9. pmc A mouse model for HIV-1 entry
    John Pietzsch
    Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 109:15859-64. 2012
    ..An antibody's ability to block viral entry in this in vivo model is a function of its bioavailability, direct neutralizing activity, and effector functions...
  10. pmc Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness
    John Pietzsch
    Laboratory of Molecular Immunology and Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, USA
    J Exp Med 207:1995-2002. 2010
    ..We conclude that the core epitope should be considered as a target for vaccine design...